Identifying Targetable Vulnerabilities to Circumvent or Overcome Venetoclax Resistance in Diffuse Large B-Cell Lymphoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Jun 19

PMID 38893249

Authors

Clare M Adams

Amanda McBride

Peter Michener

Irina Shkundina

Ramkrishna Mitra

Hyun Hwan An

Pierluigi Porcu

Christine M Eischen

Affiliations

Soon will be listed here.

Abstract

Clinical trials with single-agent venetoclax/ABT-199 (anti-apoptotic BCL2 inhibitor) revealed that diffuse large B-cell lymphoma (DLBCL) is not solely dependent on BCL2 for survival. Gaining insight into pathways/proteins that increase venetoclax sensitivity or unique vulnerabilities in venetoclax-resistant DLBCL would provide new potential treatment avenues. Therefore, we generated acquired venetoclax-resistant DLBCL cells and evaluated these together with intrinsically venetoclax-resistant and -sensitive DLBCL lines. We identified resistance mechanisms, including alterations in BCL2 family members that differed between intrinsic and acquired venetoclax resistance and increased dependencies on specific pathways. Although combination treatments with BCL2 family member inhibitors may overcome venetoclax resistance, RNA-sequencing and drug/compound screens revealed that venetoclax-resistant DLBCL cells, including those with TP53 mutation, had a preferential dependency on oxidative phosphorylation. Mitochondrial electron transport chain complex I inhibition induced venetoclax-resistant, but not venetoclax-sensitive, DLBCL cell death. Inhibition of IDH2 (mitochondrial redox regulator) synergistically overcame venetoclax resistance. Additionally, both acquired and intrinsic venetoclax-resistant DLBCL cells were similarly sensitive to inhibitors of transcription, B-cell receptor signaling, and class I histone deacetylases. These approaches were also effective in DLBCL, follicular, and marginal zone lymphoma patient samples. Our results reveal there are multiple ways to circumvent or overcome the diverse venetoclax resistance mechanisms in DLBCL and other B-cell lymphomas and identify critical targetable pathways for future clinical investigations.

References

Burger J, Wiestner A . Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer. 2018; 18(3):148-167. DOI: 10.1038/nrc.2017.121. View

Zhao S, Kanagal-Shamanna R, Navsaria L, Ok C, Zhang S, Nomie K . Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol. 2020; 95(6):623-629. DOI: 10.1002/ajh.25796. View

Wright G, Huang D, Phelan J, Coulibaly Z, Roulland S, Young R . A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell. 2020; 37(4):551-568.e14. PMC: 8459709. DOI: 10.1016/j.ccell.2020.03.015. View

Thomalla D, Beckmann L, Grimm C, Oliverio M, Meder L, Herling C . Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood. 2022; 140(20):2113-2126. PMC: 10653032. DOI: 10.1182/blood.2021014304. View

Szlavik Z, Ondi L, Csekei M, Paczal A, Szabo Z, Radics G . Structure-Guided Discovery of a Selective Mcl-1 Inhibitor with Cellular Activity. J Med Chem. 2019; 62(15):6913-6924. DOI: 10.1021/acs.jmedchem.9b00134. View

Kwiatkowski N, Zhang T, Rahl P, Abraham B, Reddy J, Ficarro S . Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014; 511(7511):616-20. PMC: 4244910. DOI: 10.1038/nature13393. View

Iqbal J, Sanger W, Horsman D, Rosenwald A, Pickering D, Dave B . BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol. 2004; 165(1):159-66. PMC: 1618550. DOI: 10.1016/s0002-9440(10)63284-1. View

Phillips D, Xiao Y, Lam L, Litvinovich E, Roberts-Rapp L, Souers A . Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). Blood Cancer J. 2015; 5:e368. PMC: 4670945. DOI: 10.1038/bcj.2015.88. View

Niu X, Zhao J, Ma J, Xie C, Edwards H, Wang G . Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. Clin Cancer Res. 2016; 22(17):4440-51. PMC: 5010519. DOI: 10.1158/1078-0432.CCR-15-3057. View

10.

Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G . Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019; 380(22):2095-2103. PMC: 11827445. DOI: 10.1056/NEJMoa1900574. View

11.

Pertea M, Kim D, Pertea G, Leek J, Salzberg S . Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat Protoc. 2016; 11(9):1650-67. PMC: 5032908. DOI: 10.1038/nprot.2016.095. View

12.

Skrtic M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, Wang Z . Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell. 2011; 20(5):674-88. PMC: 3221282. DOI: 10.1016/j.ccr.2011.10.015. View

13.

Chapuy B, Stewart C, Dunford A, Kim J, Kamburov A, Redd R . Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24(5):679-690. PMC: 6613387. DOI: 10.1038/s41591-018-0016-8. View

14.

Alaggio R, Amador C, Anagnostopoulos I, Attygalle A, de Oliveira Araujo I, Berti E . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748. PMC: 9214472. DOI: 10.1038/s41375-022-01620-2. View

15.

Nechiporuk T, Kurtz S, Nikolova O, Liu T, Jones C, DAlessandro A . The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells. Cancer Discov. 2019; 9(7):910-925. PMC: 6606338. DOI: 10.1158/2159-8290.CD-19-0125. View

16.

Nagasawa J, Mizokami A, Koshida K, Yoshida S, Naito K, Namiki M . Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int J Urol. 2006; 13(5):587-92. DOI: 10.1111/j.1442-2042.2006.01342.x. View

17.

Adams C, Mitra R, Gong J, Eischen C . Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW. Clin Cancer Res. 2017; 23(22):7119-7129. PMC: 5700812. DOI: 10.1158/1078-0432.CCR-17-1144. View

18.

Galili T, OCallaghan A, Sidi J, Sievert C . heatmaply: an R package for creating interactive cluster heatmaps for online publishing. Bioinformatics. 2017; 34(9):1600-1602. PMC: 5925766. DOI: 10.1093/bioinformatics/btx657. View

19.

Thijssen R, Tian L, Anderson M, Flensburg C, Jarratt A, Garnham A . Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy. Blood. 2022; 140(20):2127-2141. PMC: 10653037. DOI: 10.1182/blood.2022016040. View

20.

Yuda J, Will C, Phillips D, Abraham L, Alvey C, Avigdor A . Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients. Commun Med (Lond). 2023; 3(1):154. PMC: 10600239. DOI: 10.1038/s43856-023-00380-z. View